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Abstract
Background: Enterococcus spp. are particularly important etiological agents of nosocomial infections. However, the
clinical characteristics of and risk factors for enterococcal infections in clinical settings are poorly understood.
Methods: The sample included patients with Enterococcus spp. infections detected from clinical samples at
Nagasaki University Hospital between 2010 and 2011 and patients with enterococcal colonization (control patients).
In this retrospective study, the risk factors for enterococcal infections were analyzed by comparing infected and
control patients via multivariate logistic regression.
Results: A total of 182 infected (mean age, 64.6 ± 18.2 years; 114 men) and 358 control patients (patients with
enterococcal colonization) (mean age, 61.6 ± 22.4 years; 183 men) were included. Enterococcal infections were
classified as intraperitoneal (n = 87), urinary tract (n = 28), or bloodstream (n = 20) infections. Cancer and hematological
malignancies were the most common comorbidities in enterococcal infections. Carbapenem and vancomycin were
administered to 43.8 % and 57.9 % of patients infected with Enterococcus faecalis and Enterococcus faecium,
respectively. No vancomycin-resistant enterococci were isolated. Multivariate analysis identified abdominal surgery
(odds ratio [OR], 2.233; 95 % confidence interval [CI], 1.529–3.261; p≤ 0.001), structural abnormalities of the urinary tract
(OR, 2.086; 95 % CI, 1.088–4.000; p = 0.027), male sex (OR, 1.504; 95 % CI, 1.032–2.190; p = 0.033), and hypoalbuminemia
(OR, 0.731; 95 % CI, 0.555–0.963; p = 0.026) as independent risk factors for enterococcal infections. Multivariate analysis
showed abdominal surgery (OR, 2.263; 95 % CI, 1.464–3.498; p≤ 0.001), structural abnormalities of the urinary tract (OR,
2.634; 95 % CI, 1.194–5.362; p = 0.008), and hypoalbuminemia (OR, 0.668; 95 % CI, 0.490–0.911; p = 0.011) were
independent risk factors for E. faecalis infection. Finally, immunosuppressive agent use (OR, 3.837; 95 % CI, 1.397–10.541;
p = 0.009) and in situ device use (OR, 3.807; 95 % CI, 1.180–12.276; p = 0.025) were independent risk factors for E.
faecium infection.
Conclusions: These findings might inform early initiation of antimicrobial agents to improve clinical success.
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Background
Enterococci are gram-positive, catalase-negative, and
non-spore-forming facultative anaerobic bacteria. En-
terococci are generally commensal and may aid with di-
gestion and other gut metabolic pathways [1, 2]. The
two most common species responsible for enterococcal
infections in humans are Enterococcus faecalis and En-
terococcus faecium. Some Enterococcus species are used
in probiotics to treat diarrhea and improve host immun-
ity [3]. While most Enterococcus species are commensal
organisms, E. faecalis and E. faecium have become par-
ticularly important etiological agents of nosocomial infec-
tions [4, 5]; both can survive in hospital environments and
colonize patients, causing infections such as urinary tract
infections, hepatobiliary sepsis, endocarditis, surgical
wound infections, bacteremia, and neonatal sepsis. Previ-
ous reports have shown that pharyngeal or intestinal
colonization of enterococci are risk factors for enterococ-
cal bacteremia, which is associated with increased mortal-
ity, particularly in immunocompromised patients [6–8].
Enterococci, one of the most common nosocomial patho-
gens, incur a high mortality rate. The increasing use of an-
tineoplastic, biological, and other immunosuppressive
agents is one reason enterococcal infections have become
a major cause of nosocomial infections [9, 10]. This study
aimed to describe the epidemiology clinical characteristics
of and risk factors for enterococcal infections.
Methods
Study design
We performed a retrospective study of patients in whom
enterococci were detected in clinical samples between
January 1, 2010, and December 31, 2011, at Nagasaki
University Hospital, an 862-bed tertiary care and teach-
ing hospital in Nagasaki, Japan, to identify the risk fac-
tors for enterococci infection. Medical records were
reviewed for all patients with samples that were culture-
positive for enterococcal organisms. A total of 571 cases
positive for Enterococcus spp (540 inpatients, 31 out-
patients) and 583 isolates were analyzed, including 12
duplicated cases (in which the enterococci were re-
isolated >3 months after the first isolation, or mul-
tiple enterococci were isolated from a patient). This
retrospective study, including the analysis and release
of clinical data, was approved by the Ethical Commit-
tee of Nagasaki University Hospital.
Enterococcal infection criteria
Enterococcal infections were identified on the basis of
clinical symptoms (temperature > 37.5 °C and organ-
specific symptoms), laboratory data (white blood cell
count > 9100/mm3 and C-reactive protein > 0.17 mg/dL),
and bacteriological tests (monomicrobial culture or
the same organisms isolated from two organs).
Microorganisms were considered the causative patho-
gens of cellulitis or cutaneous abscesses when they
were cultured from abscess fluid, tissue specimens, or
blood. Those who did not present with distinctive
symptoms of infection but in whom enterococci had
been detected were considered to be uninfected con-
trol patients (colonized patients).
Microbiological methods
Antimicrobial resistance to ampicillin, vancomycin, li-
nezolid, imipenem, levofloxacin, and teicoplanin was de-
tected by measuring minimum inhibitory concentrations
using the PMIC-85 test panel for gram-positive bacteria
(BD Diagnosis, Sparks, MD, USA) on a BD PHOENIX
microbiology system (Becton, Dickinson and Company,
NJ, USA). Categorical interpretations were assigned ac-
cording to Clinical Laboratory Standards Institute rec-
ommendations [11].
Statistical analysis
Data were analyzed by Pearson’s χ2 test or Fisher’s exact
test when the expected count in any category was >5,
with Bonferroni post-hoc tests. Continuous non-
normally distributed variables were analyzed by the
Mann–Whitney U-test. Multivariate logistic regression
analysis with forward stepwise selection was performed
to estimate the adjusted odds ratios (ORs) and 95 % con-
fidence intervals (CIs) of the variables to determine the
potential risk factors for infection.
The Hosmer–Lemeshow test was performed as a
measure of goodness of fit. The level of significance was
set at p < 0.05. All statistical analyses were performed
using IBM SPSS for Windows version 20.0 (IBM Corp.,
Armonk, NY, USA).
Results
Study population and patient characteristics
The epidemiological variables, infection types, anti-
microbial therapies, and culture-positive specimens from
583 Enterococcus spp. case isolates are summarized in
Table 1. These corresponded to 182 infected patients
(33.7 %), including 74 (40.7 %) intra-peritoneal infec-
tions, 13 (7.1 %) intra-peritoneal infections after liver
transplantation, and 29 (15.9 %) urinary tract infections;
moreover, enterococci colonization was noted in 358
hospitalized patients. In intraperitoneal infections after
liver transplantation, the number of E. faecium infections
was significantly greater than that of E. faecalis infections
(p < 0.001). On the other hand, in urinary tract infections,
the number of E. faecalis infections was significantly
greater than that of E. faecium infections (p = 0.016). En-
terococcus spp. were identified from urine (n = 32; 17.6 %),
abscess discharge (n = 45; 24.7 %), and blood (n = 37;
20.3 %). Abscess discharge was the most common E.
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Table 1 Epidemiological variables and infection types
Total n = 182 E. faecalis n = 144 E. faecium n = 38
Age, mean (SD), years 64.6 (18.2) 65.0 (19.3) 64.8 (13.5)
Male sex n, (%) 114 (62.6) 89 (61.8) 25 (65.8)
Type of infection n, (%)
Intra-peritoneal infections 74 (40.7) 59 (41.0) 15 (39.5)
Intra-peritoneal infections after liver transplantation 13 (7.1) 4 (2.8) 9 (23.7)
Urinary tract infections 29 (15.9) 29 (20.1) 0 (0.0)
Febrile neutropenia 16 (8.8) 11 (7.6) 5 (13.2)
Bone and soft-tissue infections 17 (9.3) 14 (9.7) 3 (7.9)
Blood stream infections 20 (11.0) 15 (10.4) 5 (13.2)
Pulmonary infections 10 (5.5) 10 (6.9) 0 (0.0)
Vascular grafts infections 3 (1.6) 2 (1.4) 1 (2.6)
Comorbidity n, (%)
Cancer and hematologic malignancy 65 (35.7) 57 (39.6) 8 (21.1)
Hematologic malignancy 22 (12.1) 14 (9.7) 8 (21.1)
Solid organ transplantation 19 (10.4) 10 (6.9) 9 (23.7)
Bone marrow and stem cell transplantation 9 (4.9) 3 (2.1) 6 (15.8)
Diabetes mellitus 14 (7.7) 12 (8.3) 2 (5.3)
Collagen vascular disease 12 (6.6) 9 (6.3) 3 (7.9)
Chronic kidney disease 53 (29.1) 40 (27.8) 13 (34.2)
Structural abnormality of urinary tract 22 (12.1) 21 (14.6) 1 (2.6)
Hemodialysis 12 (6.6) 10 (6.9) 2 (5.3)
Antimicrobial therapy n, (%)
Vancomycin 48 (26.4) 26 (18.1) 22 (57.9)
Linezolid 13 (7.1) 3 (2.1) 8 (21.1)
Teicoplanin 14 (7.7) 6 (4.2) 8 (21.1)
Meropenem 37 (20.3) 37 (25.7) 0 (0.0)
Imipenem/cilastatin 15 (8.2) 15 (10.4) 0 (0.0)
Biapenem 2 (1.1) 2 (1.4) 0 (0.0)
Doripenem 9 (4.9) 9 (6.3) 0 (0.0)
Piperacillin 10 (5.5) 10 (6.9) 0 (0.0)
Tazobactam/piperacillin 18 (9.9) 18 (12.5) 0 (0.0)
Ampicillin 2 (1.1) 2 (1.4) 0 (0.0)
Sulbactam/ampicillin 6 (3.3) 6 (4.2) 0 (0.0)
Levofloxacin 21 (11.5) 21 (14.6) 0 (0.0)
Ciprofloxacin 3 (1.6) 3 (2.1) 0 (0.0)
Tosufloxacin 1 (0.5) 1 (0.7) 0 (0.0)
Combination therapy 18 (9.9) 18 (12.5) 0 (0.0)
Culture-positive specimens n, (%)
Urine 32 (17.6) 27 (18.8) 1 (2.6)
Sputum 9 (4.9) 9 (6.3) 0 (0.0)
Blood 37 (20.3) 25 (17.4) 6 (15.8)
Peritoneal fluid 32(17.6) 24 (16.7) 8 (21.1)
Pleural fluid 1 (0.5) 1 (0.7) 0 (0.0)
Bile 16 (8.8) 10 (6.9) 6 (15.8)
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faecalis culture-positive specimen type, occurring in 38
(25.7 %) infected patients. Peritoneal fluid and abscess dis-
charge were the most common E. faecium culture-positive
specimen types, with eight (21.1 %) infected patients.
The overall mean ± SD age of the patients was 64.6 ±
18.2 years, and 114 patients (62.8 %) were men. Entero-
coccal infections were most frequently found in patients
with cancer and hematologic malignancy (65 patients;
35.7 %), structural abnormalities of the urinary tract (22
patients; 12.1 %), and solid organ transplant (19 patients;
10.4 %). Cancer and hematologic malignancies (39.6 %)
and structural abnormalities (14.6 %) were most com-
mon in patients with E. faecalis infections. Meanwhile,
solid organ transplantation (23.7 %) and hematologic
malignancy (21.1 %) were most common in patients with
E. faecium infections. Compared with E. faecalis, bone
marrow and stem cell transplantation were significantly
common in E. faecium infections (p = 0.027).
Meropenem was the most commonly prescribed anti-
biotic for E. faecalis (n = 37, 25.7 %). Among the patients
infected with E. faecalis, 18 (12.5 %) received combination
therapies consisting of anti-MRSA(Methicillin-resistant
Staphylococcus aureus) agents and other antibiotics.
Vancomycin was the most commonly prescribed anti-
biotic for E. faecium infections (n = 22, 57.9 %).
Antimicrobial susceptibilities of 583 enterococcal strains
Antimicrobial susceptibility was determined for the 583
isolates. Amoxicillin resistance was observed in 1.1 % of
E. faecalis and 90.8 % of E. faecium isolates. In this
study, no vancomycin-resistant enterococci were iso-
lated, identical to results of a previous Japanese report
[12]. Imipenem resistance was found in 0.9 % of E. fae-
calis and 92.4 % of E. faecium isolates. Levofloxacin re-
sistance was found in 19.9 % of E. faecalis and 96.9 % of
E. faecium isolates. Only one E. faecium isolate had tei-
coplanin resistance. There were no linezolid-resistant
enterococci among the 550 enterococcal isolates.
Risk factors for Enterococcus spp. infection
A total of 182 infected patients and 358 colonized control
patients were compared to determine the risk factors for
Enterococcus spp. infection (Table 2). In multivariate ana-
lysis, abdominal surgery was the strongest risk factor for
enterococcal infection (adjusted OR, 2.233; 95 % CI,
1.529–3.261; p ≤ 0.001). Other significant risk factors for
infection were structural abnormalities of the urinary
tract (adjusted OR, 2.086; 95 % CI, 1.088–4.000; p =
0.027), male sex (adjusted OR, 1.504; 95 % CI, 1.032–
2.190; p = 0.033), and hypoalbuminemia (adjusted OR,
0.731; 95 % CI, 0.555–0.963; p = 0.026).
Risk factors for E. faecalis infection
A total of 144 infected and 275 control patients were
compared to determine the risk factors for E. faecalis in-
fection (Table 2). Structural abnormalities of the urinary
tract conferred the highest risk of E. faecalis infection
(adjusted OR, 2.634; 95 % CI, 1.294–5.362; p = 0.008) on
multivariate analysis. Other significant risk factors were
abdominal surgery (adjusted OR, 2.263; 95 % CI, 1.464–
3.498; p ≤ 0.001) and hypoalbuminemia (adjusted OR,
0.668; 95 % CI, 0.490–0.911; p = 0.011).
Risk factors for E. faecium infection
A total of 38 infected patients and 83 control patients
were compared to determine the risk factors for E. fae-
cium infection (Table 2). Immunosuppressive agent use
(adjusted OR, 3.837; 95 % CI, 1.397–10.541; p = 0.017)
and in situ device use (OR, 3.807; 95 % CI, 1.180–
12.276; p = 0.025) were significant risk factors for E. fae-
cium infection.
Discussion
This retrospective study analyzed the epidemiology, char-
acteristics, and risk factors for vancomycin-susceptible en-
terococcal (VSE) infections compared with colonized
control patients on the basis of medical records.
In the United States, enterococci are recognized as im-
portant causative pathogens of catheter-related blood-
stream infections, urinary tract infections, and cellulitis
[2, 9, 10].
The independent risk factors for vancomycin-resistant
enterococcal (VRE) infection were reported previously.
Kim et al. compared the VRE “infected” and “colonized”
groups and reported combined infection with bacteria
other than VRE, presence of a hemodialysis catheter,
and duration of vancomycin use were the independent
risk factors for VRE infection [13]. Olivgeris et al. re-
ported that cortisone use, third- or fourth-generation
cephalosporins, enteral nutrition, and VRE colonization
were the risk factors for developing enterococcal infec-
tion in critical ill patients [14]. Zaas et al. reported that
Table 1 Epidemiological variables and infection types (Continued)
Discharge from abscess 45(24.7) 37 (25.7) 8 (21.1)
Central venous catheter tip 4 (2.2) 4 (2.8) 0 (0.0)
Throat swab 5 (2.7) 4 (2.8) 1 (2.6)
Vascular graft 3 (1.6) 2 (1.4) 1 (2.6)
Polymicrobial culture 83 (45.6) 70 (48.6) 13 (34.2)
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Table 2 Risk factors for enterococcal infection
Enterococcal infections Enterococcus faecalis infections Enterococcus faecium infections
Infections Controls Univariate Multivariate Infections Controls Univariate Multivariate Infections Controls Univariate Multivariate
n = 182 n = 358 p value Adjusted OR
(95 % CI)
p value n = 144 n = 275 p value Adjusted OR
(95 % CI)
p value n = 38 n = 83 p value Adjusted OR
(95 % CI)
p value
Age, years, mean (SD) 64.6
(18.2)




0.187 - - 64.8(13.5) 64.7
(20.1)
0.351 - -
Sex (male), n (%) 114 (62.6) 183 (51.1) 0.011 1.504
(1.032-2.190)
0.033 89 (61.8) 142
(51.6)
0.047 - - 25 (65.8) 41 (49.4) 0.094 - -
Comorbidities, n (%)




96 (52.7) 171 (47.8) 0.274 - - 77 (53.5) 131
(47.6)
0.257 - - 19 (50.0) 40 (48.2) 0.854 - -
Chronic kidney
disease
52 (28.6) 109 (30.4) 0.653 - - 39 (27.0) 84 (30.5) 0.46 - - 13 (34.2) 25 (30.1) 0.654 - -
Structural abnormality
of the urinary tract
21 (11.5) 22 (6.1) 0.029 2.086
(1.088–4.000)
0.027 20 (13.8) 17 (6.2) 0.008 2.634
(1.294–5.362)
0.008 1 (2.6) 5 (6.0) 0.427 - -
Hemodialysis 12 (6.6) 33 (9.2) 0.297 - - 10 (6.9) 20 (7.3) 0.902 - - 2 (5.3) 13 (15.6) 0.109 - -
Therapy for
comorbidities, n (%)
Abdominal surgery 90 (49.5) 102 (28.5) 0 2.233
(1.529–3.261)
0 68 (47.2) 72 (26.2) 0 2.263
(1.464–3.498)
0 22 (57.9) 30 (36.1) 0.025 - -
Steroids 42 (23.1) 75 (20.9) 0.571 - - 23 (16.0) 47 (17.1) 0.771 - - 19 (50.0) 28 (33.7) 0.09 - -
Immunosuppressive
agents
30 (16.5) 41 (11.5) 0.102 - - 17 (11.8) 29 (10.5) 0.696 - - 13 (34.2) 12 (14.5) 0.013 3.837
(1.397–10.541)
0.009




75 (41.2) 145 (40.5) 0.875 - - 57 (39.6) 103
(37.5)
0.671 - - 18 (47.4) 42 (50.6) 0.742 - -
Using in situ
device, n (%)
120 (65.9) 190 (53.1) 0.004 - - 86 (59.7) 132
(48.0)










































0.223 - - 93.8
(68.3)
86.8 (149) 0.04 - -













the use of vancomycin, gastrointestinal procedures, dia-
betes mellitus, and acute renal failure could be risk
factors for enterococcal bloodstream infections in malig-
nant patients who colonized VRE [15]. As shown in
these reports, the risk factors of enterococcal infections,
especially VRE, are variable depending on patient back-
ground. In addition, the risk factors for VSE infections,
which are highly prevalent in Japan, remain unknown. In
our study, structural abnormalities of the urinary tract,
abdominal surgery, immunosuppressive agent use, male
sex, hypoalbuminemia, and the use of in situ devices are
the risk factors of VSE infections.
Moreover, Sugiura et al. reported that enterococci are
the most common causative pathogens of intra-
abdominal infections after pancreaticoduodenectomy
[16] and recommend accounting for enterococcal infec-
tions when selecting antimicrobials for empirical treat-
ment for intra-abdominal infections after abdominal
surgery. Furthermore, Kim et al. report that liver trans-
plantations are an independent risk factor for entero-
cocci intra-abdominal infections [17]. A high incidence
of enterococcal infection was also found in the current
study, and 17 of the 42 liver transplantations performed
during 2010–2011 at our hospital were complicated by
enterococcal infections (which corresponds to a high
complication incidence of 42 %). In addition, according
to an analysis of isolates from intra-abdominal infections
after liver transplantations, the isolation frequency of E.
faecium (23.7 %) is higher than that of E. faecalis (2.8 %)
(p < 0.001). Enterococci, particularly E. faecium, are con-
sidered important causative pathogens of infections in
liver transplantation recipients. In cases in which
healthcare-associated infections are suspected after liver
transplantation, the intra-abdominal infection complica-
tion guidelines of the 2010 Surgical Infection Society
and Infectious Diseases Society of America recommend
selecting antimicrobial agents that cover enterococci
(e.g., ampicillin, piperacillin/tazobactam, vancomycin) to
treat infections in patients administered antibiotics that
do not cover enterococci, such as cephalosporin; in im-
munocompromised patients; or patients with valvular
heart disease, prosthetic heart valves, or artificial blood
vessels [18]. In addition, the resistance to anti-MRSA
drugs, especially the increasing prevalence of VRE
present in nosocomial infections, has become a major
problem in the United States and Europe [5]. Since VRE
was first reported as a VanA type-resistant E. faecium in
1988 in the United Kingdom and France, and VanB
type-resistant E. faecalis in 1989 [19, 20], its prevalence
has been increasing annually; reports from the United
States indicate that 62.3–82.6 % of E. faecium isolates de-
tected in nosocomial infections are VRE [9]. In Europe, it
is most prevalent in Ireland (44.0 %), followed by Portugal
(23.3 %) and Greece (17.1 %) [5, 21]. In China, the
prevalence of vancomycin-resistant E. faecium is 2.7 %
while that of vancomycin-resistant E. faecalis is 6.5 % [22];
the detection rates in Asia, including Japan, are low [12,
23], and these species were not isolated in the present
study.
Interestingly, E. faecalis was identified as the causative
pathogen in all cases of enterococcal urinary tract infec-
tions in the present study. Enterococci are causative
pathogens in complicated urinary tract infections and
feature a high isolation frequency [24]. Urine from chil-
dren with congenital urinary tract disorders shows a
high frequency of E. faecalis isolation [25]; in the present
study as well, nearly all cases involving E. faecalis iso-
lated from the urine were accompanied by congenital
and acquired urinary tract disorders. Moreover, the fre-
quency of E. faecalis isolation in bacterial cultures from
ureteral stents is reportedly high [26]; likewise, in the
present study, cases with acquired urinary tract disorders
and E. faecalis isolation coincided with the presence of
artificial devices from procedures such as nephrostomies
and stent placements. Many factors related to the onset
of urinary tract infection by E. faecalis have been re-
ported. For example, enterococcal polysaccharide anti-
gen is reportedly involved in the onset of ascending
urinary tract infections since it binds to epithelial cells
followed by biofilm formation and/or resistance to
phagocytosis by polymorphonuclear leukocytes [27]. On
the other hand, fewer reports have examined the patho-
genicity of E. faecium affecting the onset of urinary tract
infection than those on E. faecalis [10], which may be re-
lated to the results of our present clinical study. Struc-
tural abnormalities of the urinary tract might be unique
compared with the risk factors of VRE infections, mainly
caused by E.faecium, indicating that we should closely
monitor patients with primary or secondary urinary tract
abnormalities, stent placement, and nephrostomy for
VSE infections, especially E. faecalis.
The use of immunosuppressive agents was an inde-
pendent risk factor for E. faecium infection. Unlike E.
faecalis, E. faecium recognizes peptidoglycan differences
and has different acid production mechanisms that result
in growth rate differences [2]. The recently increasing in-
cidences of collagen diseases, hematologic malignancies,
and solid tumors are thought to be related to increases in
the number of patients undergoing immunosuppressive
therapy; these patients are more likely to receive penicillin
and cephalosporin antibiotics. Consequently, increased E.
faecium levels have been reported with changes in the gut
microbiota of the large and small intestines [28].
Our present study identified male sex and hypoalbu-
minemia as independent risk factors of enterococcal in-
fections. However, these are not specific to enterococcal
infections. There have been several reports on the cor-
relation between sex and infection prognosis. Angele et al.
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reported that men have poorer prognosis of septi-
cemia than women, and the main reasons include its
correlation with male sex steroids, X-chromosome
mosaicism, etc. [29]. Hypoalbuminemia is also a
known risk factor related to the onset of and mortal-
ity caused by various infections [30].
The mortality rates of enterococcal infections includ-
ing VRE are high (25–50 %) since they often develop in
compromised hosts [31–37]. Enterococci are not highly
pathogenic per se, and their survival rates mainly depend
on underlying disease severity. However, the mortality
rates of enterococcal infections in the present study
(8.2 %) were low compared to those of previous reports.
The likely reasons for this are as follows: VRE was not
detected in this study; anti-MRSA agents such as vanco-
mycin were immediately administered against E. fae-
cium, and treatment with appropriate antimicrobial
agents was administered during the early stages of onset;
and nearly all subjects were inpatients undergoing care-
ful pathologic monitoring. Patients who contracted E.
faecium infections from carriers had significantly longer
hospital stays on univariate analysis. This is probably be-
cause of the increased condition severity of the patients
with E. faecium infections as well as a high degree of
drug resistance that necessitated long-term antimicrobial
agent use [35–37].
Conclusions
This study revealed the independent risk factors for E.
faecalis and faecium infections. Significant risk factors
for infection on multivariate analysis were structural ab-
normalities of the urinary tract, abdominal surgery, im-
munosuppressive agent use, in situ device use, male sex,
and hypoalbuminemia. There was a significant correl-
ation between liver transplantations and infections with
E. faecium compared to E. faecalis. In cases complicated
by bacteremia or intra-abdominal infections, enterococci
are pathogenic microorganisms with a high mortality
rate that must be handled carefully. Studies on risk factors
for the onset of enterococcal infections provide useful in-
formation for clinicians, enabling improved prognosis, re-
duced hospitalization, and the proper use of antimicrobial
agents through early treatment intervention. Nevertheless,
additional prospective studies are necessary to confirm
the present findings.
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